Английская Википедия:Frunevetmab
Шаблон:Short description Шаблон:Use American English Шаблон:Use dmy dates Шаблон:Infobox drug
Frunevetmab, sold under the brand name Solensia, is a medication used to treat pain associated with osteoarthritis in cats.[1]
It is the first monoclonal antibody new animal drug approved by the U.S. Food and Drug Administration (FDA) for use in any animal species.[1]
Frunevetmab is the international nonproprietary name (INN).[2]
Clinical usage
Frunevetmab is a cat-specific monoclonal antibody (a type of protein) designed to recognize and attach to a protein called nerve growth factor (NGF) that is involved in the regulation of pain.[1] When frunevetmab binds to NGF, it prevents the pain signal from reaching the brain.[1]
Frunevetmab is indicated for the alleviation of pain associated with osteoarthritis in cats.[1][3]
The most common side effects seen in cats include vomiting, diarrhea, injection site pain, scabbing on the head and neck, dermatitis, and pruritus (itchy skin).[1]
History
In February 2021, Frunevetmab was approved for medical use in the European Union.[3]
In January 2022, the following year, Frunevetmab was approved for medical use in the United States.[1][4]
Development as a potential drug for humans was stopped due to risk concerns over worsening osteoarthritis. [5]
See also
References
Шаблон:Reflist Шаблон:HHS content
Bibliography
External links
Шаблон:Analgesics Шаблон:Portal bar
- ↑ 1,0 1,1 1,2 1,3 1,4 1,5 1,6 Шаблон:Cite press release Шаблон:PD-notice
- ↑ Шаблон:Cite journal
- ↑ 3,0 3,1 Ошибка цитирования Неверный тег
<ref>; для сносокSolensia EPARне указан текст - ↑ Шаблон:Cite web
- ↑ Шаблон:Cite web
